The Ministry of Industry and Trade warned about the risk of immunoglobulin shortages in the Russian Federation due to the fact that the established maximum selling price for the drug is low. This was reported to TASS by the press service of the ministry.
“In June, the Ministry of Industry and Trade of Russia informed Roszdravnadzor about the risk of a inventory shortage of INN “normal human immunoglobulin” due to the low established maximum selling price for this drug, as well as due to the insufficient amount and high cost of raw materials (blood plasma) necessary for the production of the drug,” the ministry noted.
The Ministry of Industry and Trade regularly monitors the availability of medicines on the Russian market, including from the VED list. From time to time, various regions report to the ministry about the lack of immunoglobulin. The gap is bridged with the involvement of Russian manufacturers. In addition, according to the manufacturer of immunoglobulin, AO “NPO “Microgen”, all applications received by the organization about the need to supply the drug are satisfied within the shortest possible timeframe.
As it became known earlier, Russian patients with congenital immune disorders receive insufficient quantities of Immunoglobulin.
